Top

Gepubliceerd in:

01-10-2011

Exacerbation history is associated with medication and appointment adherence in MS

Auteurs: Laura M. Hancock, Jared M. Bruce, Sharon G. Lynch

Gepubliceerd in: Journal of Behavioral Medicine | Uitgave 5/2011

Abstract

Disease-modifying treatments are designed to prevent exacerbations in multiple sclerosis (MS). To date, few studies have examined the relationship between disease activity and treatment adherence in MS. The primary aim of this study was to examine the association between disease activity (e.g., annualized relapse rates), medication adherence, and appointment adherence in relapsing-remitting MS. Retrospective exacerbation and appointment data were collected and used to predict prospective medication adherence. Results indicated that patients with higher annualized relapse rates missed fewer doses of medication and were less likely to miss appointments. Conversely, patients with relatively stable disease were more likely to demonstrate poor medication adherence and poor appointment adherence. Patients who missed more appointments also missed more doses of their disease modifying medication. Future studies may wish to examine clinical methods designed to improve immunotherapy adherence among patients who are in relatively symptom-free stages of relapsing-remitting MS.

vorige artikel Use of voter registration records to recruit a representative sample

volgende artikel Psychosocial predictors of smoking among secondary school students in Al-Hassa, Saudi Arabia

Anderson, D. W., Ellenberg, J. H., Leventhal, C. M., Reingold, S. C., Rodriguez, M., & Silberberg, D. H. (1992). Revised estimate of the prevalence of multiple sclerosis in the United States. Annals of Neurology, 31, 333–336. doi:10.1002/ana.410310317.PubMedCrossRef

Arnett, P. A., Barwick, F. H., & Beeney, J. E. (2008). Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society, 14, 691–724.PubMed

Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231, 29–34.CrossRef

Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31, 698–705.PubMedCrossRef

Bruce, J. M., Bruce, A. S., & Arnett, P. A. (2007a). Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. Journal of the International Neuropsychological Society, 13, 544–548.PubMedCrossRef

Bruce, J. M., Hancock, L., Arnett, P., & Lynch, S. (2010a). Treatment adherence in multiple sclerosis: Association with emotional status, personality, and cognition. Journal of Behavioral Medicine, 33, 219–227.PubMedCrossRef

Bruce, J. M., Hancock, L., & Lynch, S. (2010b). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16, 112–120.PubMedCrossRef

Bruce, J. M., Polen, D., & Arnett, P. A. (2007b). Pain and affective memory biases interact to predict depressive symptoms in multiple sclerosis. Multiple Sclerosis, 13, 58–66.PubMedCrossRef

Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of therapy switching. Journal of the Neurological Sciences, 259, 104–108.PubMedCrossRef

Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., et al. (2001). Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet, 357, 1576–1582.PubMedCrossRef

Coyle, P. K. (2008). Early treatment of multiple sclerosis to prevent neurologic damage. Neurology, 71, S3–S7.PubMedCrossRef

Coyle, P. K. (2009). Disease-modifying agents in multiple sclerosis. Annals of Indian Academy of Neurology, 12, 273–282. doi:10.4103/0972-2327.58280.PubMedCrossRef

Cramer, J. A. (1998). Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. The American Journal of Managed Care, 4, 1563–1568.PubMed

Cree, B. A. C., Khan, O., Bourdette, D., Goodin, D. S., Cohen, J. A., Marrie, R. A., et al. (2004). Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 63, 2039–2045.PubMed

Davis, M. C., Tucker, C. M., & Fennell, R. S. (1996). Family behavior, adaptation, and treatment adherence of pediatric nephrology patients. Pediatric Nephrology, 10, 160–166.PubMed

Dietz, E., Clum, G. A., Chung, S. E., Leonard, L., Murphy, D. A., Perez, L. V., et al. (2010). Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. Journal of Adolescent Health, 46, 278–283.PubMedCrossRef

Duff, A., & Latchford, G. J. (2010). Motivational interviewing for adherence problems in cystic fibrosis. Pediatric Pulmonology, 45, 211–220.PubMed

Finney, J., Lemanek, K. L., Brophy, C. J., & Cataldo, M. F. (1990). Pediatric appointment keeping: Improving adherence in a primary care allergy clinic. Journal of Pediatric Psychology, 15, 571–579.PubMedCrossRef

Fraser, C., Hadjimichael, O., & Vollmer, T. (2003). Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. Journal of Neuroscience Nursing, 35, 163–174.PubMedCrossRef

Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology, 71, 8–13.CrossRef

Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., Halper, J., Likosky, W. H., Lublin, F. D., et al. (2002). Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines. Neurology, 58, 169–178.PubMed

Hobart, J., Freeman, J., & Thompson, A. (2000). Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain, 123, 1027–1040.PubMedCrossRef

Interian, A., Martinez, I., Rios, L. I., Krejci, J., & Guarnaccia, P. J. (2010). Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos. Cultural Diversity and Ethnic Minority Psychology, 16, 215–225. doi:10.1037/a0016072.PubMedCrossRef

Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., et al. (2001). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. American Journal of Opthamology, 131, 898–904.

Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39, 285–294.PubMedCrossRef

Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45, 1268–1276.PubMed

Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., et al. (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242–1249.PubMedCrossRef

Karter, A. J., Parker, M. M., Moffet, H. H., Ahmed, A., Ferrara, A., Liu, J. Y., et al. (2004). Missed appointments and poor glycemic control: An opportunity to identify high-risk diabetic patients. Medical Care, 42, 110–115.PubMedCrossRef

Kieseier, B. C., Wiendl, H., Leussink, V. I., & Stuve, O. (2008). Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 255, 15–21.PubMedCrossRef

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology, 33, 1444–1452.PubMed

Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911.PubMed

Maxwell, S., Maljanian, R., Horowitz, S., Pianka, M. A., Cabrera, Y., & Greene, J. (2001). Effectiveness of reminder systems on appointment adherence rates. Journal of Health Care for the Poor and Underserved, 12, 504–514.PubMed

McClure, J. B., Catz, S. L., & Brantley, P. J. (1999). Early appointment adherence among persons living with HIV. AIDS and Behavior, 3, 157–165.CrossRef

Medley, A. R., & Powell, T. (2010). Motivational interviewing to promote self-awareness and engagement in rehabilitation following acquired brain injury: A conceptual review. Neuropsychological Rehabilitation, Epub ahead of print.

Mitsonis, C. I., Zervas, I. M., Mitropoulos, P. A., Dimopoulos, N. P., Soldatos, C. R., & Potagas, C. M. (2008). The impact of stressful life events on risk of relapse in women with multiple sclerosis: A prospective study. European Psychiatry, 23, 497–504. doi:10.1016/j.eurpsy.2008.06.003.PubMedCrossRef

Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125–132.PubMedCrossRef

Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Archives of Neurology, 54, 531–533.PubMed

Mollon, B., Holbrook, A. M., Keshavjee, K., Troyan, S., Gaebel, K., & Thabane, L. (2008). Automated telephone reminder messages can assist electronic diabetes care. Journal of Telemedicine and Telecare, 14, 32–36. doi:10.1258/jtt.2007.070702.PubMedCrossRef

Moore, C. G., Wilson-Witherspoon, P., & Probst, J. C. (2001). Time and money: Effects of no-shows at a family practice residency clinic. Family Medicine, 33, 522–527.PubMed

Outlaw, A., Naar-King, S., Green-Jones, M., Wright, K., Condon, K., Sherry, L., & Janisse, H. (2010). Brief report: Predictors of optimal HIV appointment adherence in minority youth: A prospective study. Journal of Pediatric Psychology, 35, 1011–1015. doi:10.1093/jpepsy/jsq002.

Patti, F. (2009). Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Preference and Adherence, 4, 1–9.

Pesata, V., Palliga, G., & Webb, A. A. (1999). A descriptive study of missed appointments: Families’ perceptions of barriers to care. Journal of Pediatric Health Care, 13, 178–182.PubMedCrossRef

Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58, 840–846.PubMedCrossRef

Pryse-Phillips, W., & Costello, F. (2001). The epidemiology of multiple sclerosis. New York: Marcel Dekker, Inc.

Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306–309. doi:10.1191/1352458505ms1173oa.PubMedCrossRef

Satiani, B., Miller, S., & Patel, D. (2009). No-show rates in the vascular laboratory: Analysis and possible solutions. Journal of Vascular and International Radiology, 20, 87–91. doi:10.1016/j.jvir.2008.09.027.CrossRef

Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., et al. (1965). Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Sciences, 122, 552–568.CrossRef

Steinberg, S. C., Faris, R. J., Chang, C. F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to inteferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clinical Drug Investigation, 30, 89–100.PubMedCrossRef

The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655–661.

Uribe, A. G., Ho, K. T., Agee, B., McGwin, G., Fessler, B. J., & Bastian, H. M. (2004). Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: Data from the LUMINA cohort. Lupus, 13, 561–568. doi:10.1191/0961203304lu1061oa.PubMedCrossRef

Walker, E. A., Molitch, M., Kramer, M. K., Kahn, S., Ma, Y., Edelstein, S., et al. (2006). Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, 29, 1997–2002.PubMedCrossRef

Wallin, M. T., Page, W. F., & Kurtzke, J. F. (2004). Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Annals of Neurology, 55, 65–71.PubMedCrossRef

Walther, E. U., & Hohlfeld, R. (1999). Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology, 53, 1622–1627.PubMed

World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. Retrieved from http://www.who.int/chp/knowledge/publications/adherence_report/en/.

Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., et al. (2003). A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences, 216, 113–118.PubMedCrossRef

Titel: Exacerbation history is associated with medication and appointment adherence in MS
Auteurs: Laura M. Hancock
Jared M. Bruce
Sharon G. Lynch
Publicatiedatum: 01-10-2011
Uitgeverij: Springer US
Gepubliceerd in: Journal of Behavioral Medicine / Uitgave 5/2011
Print ISSN: 0160-7715
Elektronisch ISSN: 1573-3521
DOI: https://doi.org/10.1007/s10865-011-9316-x

Andere artikelen Uitgave 5/2011

Motivational interviewing + feedback intervention to reduce alcohol-exposed pregnancy risk among college binge drinkers: determinants and patterns of response

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

Exacerbation history is associated with medication and appointment adherence in MS

Abstract

Andere artikelen Uitgave 5/2011

Motivational interviewing + feedback intervention to reduce alcohol-exposed pregnancy risk among college binge drinkers: determinants and patterns of response

Adaptive style and physiological reactivity during a laboratory stress paradigm in children with cancer and healthy controls

Causal attributions among patients undergoing coronary artery bypass surgery: gender aspects and relation to depressive symptomatology

Religion and healthy lifestyle behaviors among postmenopausal women: the women’s health initiative

Use of voter registration records to recruit a representative sample

Interpersonal influences on patients’ surgical decision making: the role of close others

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Motivational interviewing + feedback intervention to reduce alcohol-exposed pregnancy risk among college binge drinkers: determinants and patterns of response

Adaptive style and physiological reactivity during a laboratory stress paradigm in children with cancer and healthy controls

Causal attributions among patients undergoing coronary artery bypass surgery: gender aspects and relation to depressive symptomatology

Religion and healthy lifestyle behaviors among postmenopausal women: the women’s health initiative

Use of voter registration records to recruit a representative sample

Interpersonal influences on patients’ surgical decision making: the role of close others